Whalesbook
India Business Sees Sales Surge, But Profits Tumble
Dr. Reddy's Laboratories has achieved a significant turnaround in its India business, with sales jumping 20% year-on-year in Q4 FY26 and rising 16% for the full year. This growth is driven by a strategic focus on innovative products and improved operational efficiency. India contributed about 18-19% to the company's total FY26 revenue of ₹33,593 crore. The stable domestic market provides a buffer against overseas market volatility.
However, this revenue performance is overshadowed by an 86% year-on-year drop in Q4 FY26 net profit to ₹220 crore. This decline was mainly due to significant one-off charges, such as shelf stock adjustments, R&D impairments, and provisions for VAT and new labour codes. Full-year profit before tax also fell 29% to ₹5,481 crore.
Chronic Therapy Gap Limits Market Share
While Dr. Reddy's is outpacing market growth, its portfolio composition differs significantly from Indian Pharmaceutical Market (IPM) trends. The IPM is increasingly focusing on chronic therapies, which grew 14.2% year-on-year as of April 2026, versus 7.8% for acute therapies. Chronic segments, including cardiac and anti-diabetic drugs, now represent over 40% of the IPM.
In contrast, Dr. Reddy's chronic therapies make up only about one-fifth of its India revenue. Analysts see this under-representation as a key barrier preventing the company from joining the top tier of domestic pharmaceutical players. Management acknowledges this imbalance and is reportedly working to expand its chronic therapy offerings through new launches and potential acquisitions.
Dr. Reddy's vs. Peers: Valuation and Market Trends
Dr. Reddy's had a P/E ratio of around 17.5-19.5 as of May 2026 and a market capitalization near ₹1.06 lakh crore. This valuation contrasts with larger peers like Sun Pharmaceutical Industries, which trades at a P/E of about 40.3 with a market cap of ₹4.4 lakh crore. Cipla and Zydus Lifesciences have P/E ratios closer to Dr. Reddy's, at around 23-24 and 19.5, with market caps of roughly ₹1.05 lakh crore and ₹0.95 lakh crore.
The Indian pharmaceutical market showed resilience, growing about 8.8% in FY26. There was a notable shift towards high-value chronic treatments and growing interest in GLP-1 therapies for diabetes. Dr. Reddy's shares have shown volatility, trading near 52-week lows at times in May 2026 after its Q4 results were released.
Profit Drop Sparks Analyst Skepticism
Despite revenue recovery, the sharp drop in Q4 FY26 profitability and margins, caused by substantial one-off expenses, casts doubt on the immediate outlook. Brokerage sentiment is divided.
Kotak Institutional Equities maintains a 'Reduce' rating with a target price of ₹1,175, citing margin misses and missed EBITDA estimates. Morgan Stanley holds an 'Equal-weight' rating but lowered its target to ₹1,195. Goldman Sachs reiterates a 'Sell' rating with a target of ₹1,050, pointing to revenue and EBITDA margin misses from lower lenalidomide sales and shelf stock adjustments. Motilal Oswal maintains a 'Neutral' stance with a target of ₹1,195, noting decelerating earnings.
The consensus analyst rating is 'Hold' with an average target price around ₹1,293, suggesting a cautious outlook for the stock's immediate upside. The persistent gap in chronic therapies remains a key structural weakness, potentially limiting market share gains against competitors with more balanced portfolios.
Looking Ahead: Innovation and Strategic Priorities
Dr. Reddy's is banking on the growth of innovative products like semaglutide and planned biosimilar launches to drive future growth and improve margins. Management guidance predicts significant pen sales for semaglutide and capacity expansion by FY28.
However, medium-term performance will depend on limited competition for semaglutide in key markets and the successful launch of products like Abatacept in the US. The strategic focus remains on addressing the underweighted chronic therapy segment, crucial for sustained, broad-based growth and solidifying its position in India's evolving pharmaceutical market.